New drugs and combinations in the palliative treatment of colon and rectal cancer

G. D. Beretta, M. A. Pessi, P. Poletti, S. Mosconi, R. Labianca

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is a common disease. The overall survival has improved only marginally in recent decades despite advances in surgery and early detection. Potentially curative resection at disease presentation can be performed only in 70-80% of the patients, and overall survival at 5 years is less than 60%. Advanced disease is associated with a poor prognosis. Treatment for advanced colorectal cancer has nevertheless made progress in the last few years. Systemic chemotherapy doubles the survival of these patients compared to untreated controls. Chemotherapy has demonstrated effective palliation, improvement of quality of life (QoL) and symptom improvement in such patients. For nearly four decades, fluorouracil (5FU) has been the mainstay of treatment. New compounds active against colorectal cancer are now available. Several studies on this topic are ongoing.

Original languageEnglish
Pages (from-to)595-600
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume27
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

Drug Combinations
Rectal Neoplasms
Palliative Care
Colonic Neoplasms
Colorectal Neoplasms
Fluorouracil
Survival
Drug Therapy
Quality of Life
Therapeutics

Keywords

  • Chemotherapy
  • Colorectal cancer

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

New drugs and combinations in the palliative treatment of colon and rectal cancer. / Beretta, G. D.; Pessi, M. A.; Poletti, P.; Mosconi, S.; Labianca, R.

In: European Journal of Surgical Oncology, Vol. 27, No. 6, 2001, p. 595-600.

Research output: Contribution to journalArticle

Beretta, G. D. ; Pessi, M. A. ; Poletti, P. ; Mosconi, S. ; Labianca, R. / New drugs and combinations in the palliative treatment of colon and rectal cancer. In: European Journal of Surgical Oncology. 2001 ; Vol. 27, No. 6. pp. 595-600.
@article{ca880c185e954b78aad0ff77a4fb2626,
title = "New drugs and combinations in the palliative treatment of colon and rectal cancer",
abstract = "Colorectal cancer (CRC) is a common disease. The overall survival has improved only marginally in recent decades despite advances in surgery and early detection. Potentially curative resection at disease presentation can be performed only in 70-80{\%} of the patients, and overall survival at 5 years is less than 60{\%}. Advanced disease is associated with a poor prognosis. Treatment for advanced colorectal cancer has nevertheless made progress in the last few years. Systemic chemotherapy doubles the survival of these patients compared to untreated controls. Chemotherapy has demonstrated effective palliation, improvement of quality of life (QoL) and symptom improvement in such patients. For nearly four decades, fluorouracil (5FU) has been the mainstay of treatment. New compounds active against colorectal cancer are now available. Several studies on this topic are ongoing.",
keywords = "Chemotherapy, Colorectal cancer",
author = "Beretta, {G. D.} and Pessi, {M. A.} and P. Poletti and S. Mosconi and R. Labianca",
year = "2001",
doi = "10.1053/ejso.2001.1128",
language = "English",
volume = "27",
pages = "595--600",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - New drugs and combinations in the palliative treatment of colon and rectal cancer

AU - Beretta, G. D.

AU - Pessi, M. A.

AU - Poletti, P.

AU - Mosconi, S.

AU - Labianca, R.

PY - 2001

Y1 - 2001

N2 - Colorectal cancer (CRC) is a common disease. The overall survival has improved only marginally in recent decades despite advances in surgery and early detection. Potentially curative resection at disease presentation can be performed only in 70-80% of the patients, and overall survival at 5 years is less than 60%. Advanced disease is associated with a poor prognosis. Treatment for advanced colorectal cancer has nevertheless made progress in the last few years. Systemic chemotherapy doubles the survival of these patients compared to untreated controls. Chemotherapy has demonstrated effective palliation, improvement of quality of life (QoL) and symptom improvement in such patients. For nearly four decades, fluorouracil (5FU) has been the mainstay of treatment. New compounds active against colorectal cancer are now available. Several studies on this topic are ongoing.

AB - Colorectal cancer (CRC) is a common disease. The overall survival has improved only marginally in recent decades despite advances in surgery and early detection. Potentially curative resection at disease presentation can be performed only in 70-80% of the patients, and overall survival at 5 years is less than 60%. Advanced disease is associated with a poor prognosis. Treatment for advanced colorectal cancer has nevertheless made progress in the last few years. Systemic chemotherapy doubles the survival of these patients compared to untreated controls. Chemotherapy has demonstrated effective palliation, improvement of quality of life (QoL) and symptom improvement in such patients. For nearly four decades, fluorouracil (5FU) has been the mainstay of treatment. New compounds active against colorectal cancer are now available. Several studies on this topic are ongoing.

KW - Chemotherapy

KW - Colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=0034857599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034857599&partnerID=8YFLogxK

U2 - 10.1053/ejso.2001.1128

DO - 10.1053/ejso.2001.1128

M3 - Article

VL - 27

SP - 595

EP - 600

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 6

ER -